2018 Oligonucleotide Therapeutics Education Workshop
Designing Oligo Therapeutics and Understanding Their PK
……………
Chemistry of Oligonucleotide Therapeutics 101
Mano Manoharan, PhD, Alnylam Pharmaceuticals
Oligonucleotides as a New Therapeutic Class: Progress Report & Prescription
Paul Burke, PhD, Burke Bioventures LLC
Unraveling the Mechanisms of ASO Mediated Toxicity
Sebastien Burel, PhD, Ionis Pharmaceuticals
Screening for Immunostimulation
Arthur M. Krieg, MD, Checkmate Pharmaceuticals
Regulatory Applications of a Nonclinical Database for Oligonucleotide Therapeutics at U.S. FDA
Emily Place, PhD, MPH, U.S. Food and Drug Administration
How a Drug is Assessed Once It’s in Clinical Trials: A perspective from a Clinical Pharm Reviewer
Bart Rogers PharmD, PhD, Office of Clinical Pharmacology, U.S. FDA
Q&A Panel (part of educational workshop)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Alejandra Gonzalez-Duarte, MD, National Institute of Medical Sciences and Nutrition–Salvador Zubiran, Mexico
2018 Annual Meeting – Welcome
……………
Welcome & Opening Remarks
OTS President: Arthur M. Krieg, MD, Checkmate Pharmaceuticals Event Chairperson: Steven F. Dowdy, PhD, University of California, San Diego
2018 Annual Meeting Keynote
……………
Keynote Presentation: Genome Editing Technologies and Beyond
Feng Zhang, PhD, Broad Institute of MIT and Harvard
2018 Annual Meeting Award Winner Presentations
……………
Dr. Alan M. Gewirtz Memorial Scholarship Award Aiming for Ideality in the Age of Biomolecules
Justine N. deGruyter, The Scripps Research Institute Kyle Knouse, The Scripps Research Institute
Young Investigator Award Development of Nanomaterials for mRNA Therapeutics and Genome Editing
Yizhou Dong, PhD, The Ohio State University
2018 Annual Meeting Lifetime Achievement
……………
Lifetime Achievement Award Chemical Synthesis DNA/RNA and Biological Activity of Selected Analogues
Marvin H. Caruthers, PhD, University of Colorado